The New York Times
CHICAGO — The experimental drug PLX4032, which reverses the effects of a
mutation found in certain , is considered a prime example of the
“targeted” therapies of the future. The drug —
the subject of a three-part series in The New York Times
in February — produced seemingly miraculous results in some patients
with ... read more
Find a Doctor/Researcher
Make an Appointment
Refer a Patient
Make a Gift
Penn Cancer Network
